Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
Nom du journal : J Clin Oncol
Année : 2014
Volume : 32
Page de départ : 424
Page de fin : 430